A study conducted at the State University of Campinas (UNICAMP) in Brazil investigated the process of muscle pain ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Topline data were announced from 2 phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Viatris (NASDAQ:VTRS) stock rises 5% premarket as Phase 3 trials show success for non-opioid pain therapy, meloxicam as a ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

Intervertebral disc disease (IVDD) occurs when discs bulge or burst, compressing the spinal cord. 1 Symptoms range from pain ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.